Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Next Previous
Search
Trial Profile

Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Sialorrhoea
  • Focus Registrational; Therapeutic Use
  • Acronyms SIAXI
  • Sponsors Merz Pharma

    • Most Recent Events

    • 18 Sep 2022 Results presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
    • 01 Dec 2020 According to a Merz Therapeutics media release, based on this study, the company announced that Health Canada notice of compliance for XEOMIN (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, associated with neurological disorders in adult patients.
    • 29 May 2019 According to Merz North America Media release, based on the data from this trial, Xeomin (incobotulinumtoxinA) has received the European approval for the symptomatic treatment of chronic sialorrhea (drooling) due to neurological disorders in adult patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top